Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
GSK flags up pipeline as HIV drugs help it beat profit forecasts

GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

Published
30 July 2015
From
Reuters
Intensification of antiretroviral therapy reduces risk of late-term mother-to-child HIV transmission

Maternal and infant antiretroviral therapy (ART) intensification is very effective in preventing HIV transmission during labour and birth in pregnant women with HIV in Thailand who present late

Published
29 July 2015
By
Carole Leach-Lemens
Implant and injectable hormonal contraception most effective methods for women living with HIV

Hormonal contraceptive methods are highly effective in reducing the risk of pregnancy in women living with HIV whether on antiretroviral therapy (ART) or not, according to an evaluation

Published
29 July 2015
By
Carole Leach-Lemens
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment for pregnant women with HIV –

Published
28 July 2015
By
Liz Highleyman
Stribild Superior to Boosted Atazanavir in Treatment-Naive Women

Stribild proved virologically superior to atazanavir/ritonavir plus tenofovir/emtricitabine (TDF/FTC) at 48 weeks in WAVES, an international trial in 575 antiretroviral-naive women. No one in the Stribild arm had emergent resistance upon virologic failure, compared with 3 women in the atazanavir arm.

Published
27 July 2015
From
NATAP
'Molecular microscope' finds hidden AIDS virus in the body

Researchers have developed a sophisticated new probe that detects HIV’s hiding places inside and outside of cells. Insights from this high-powered molecular microscope, revealed at an international AIDS conference last week, may clarify critical questions about HIV persistence and, ultimately, about how to rid the body of the virus.

Published
27 July 2015
From
Science
Gay youth PrEP study finds good retention and reasonable adherence

A US study of pre-exposure prophylaxis (PrEP) in 200 young gay and bisexual men aged 18-22 found reasonable levels of adherence. Adherence was highest in those

Published
24 July 2015
By
Gus Cairns
The Day the HIV Treatment Pendulum Stopped Swinging

Normally at scientific conferences, even when study findings are considered to be major, a single researcher stands at a podium for 10 or 15 minutes, takes the audience on a guided PowerPoint tour of charts and graphs, receives a round of applause, and fields a few questions. Then the session moves on to its next topic. The presentation of the START findings was different.

Published
23 July 2015
From
The Body Pro
New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related

Published
23 July 2015
By
Liz Highleyman
← First12345...393Next →

Filter by country